Apollon Wealth Management LLC Decreases Stock Holdings in Zoetis Inc. $ZTS

Apollon Wealth Management LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 34.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,894 shares of the company’s stock after selling 5,812 shares during the period. Apollon Wealth Management LLC’s holdings in Zoetis were worth $1,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of ZTS. Nova Wealth Management Inc. bought a new position in shares of Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC purchased a new position in Zoetis in the first quarter worth $27,000. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. REAP Financial Group LLC lifted its holdings in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC boosted its position in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $126.37 on Wednesday. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The company has a market cap of $55.69 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 2.74 and a beta of 0.97. The company’s 50 day moving average is $126.27 and its 200 day moving average is $142.24.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 35.69%.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZTS. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Barclays assumed coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. Finally, Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.